AMRX Q4 2017 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$293M-1.7% YoY

Gross Profit

$151M51.6% margin

Operating Income

$79M26.9% margin

Net Income

$62M21.0% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

+15.2%

Cash Flow

Operating Cash Flow

$65M

Free Cash Flow

$41M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$1.7B

Stockholders' Equity

-$386M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$293M	$299M	-1.7%
Gross Profit	$151M	$177M	-14.3%
Operating Income	$79M	$92M	-14.4%
Net Income	$62M	$54M	+14.2%